The Zhitong Finance App learned that Kangji Healthcare (09997) rose more than 4%, reaching a high of HK$10.58 since the end of September 2021. As of press release, it rose 3.94% to HK$10.56, with a turnover of HK$9.4029 million.

Goldman Sachs recently reported that by upgrading the company's rating from “neutral” to “buy”, the profit per share is expected to reach 29% in 2022-24; the valuation is relatively attractive. The target price rose from HK$7.6 to HK$13.7, reflecting the high visibility of minimally invasive surgery (MIS) after the Lunar New Year, and the gradual return to normal patient flow, and the impact of centralized drug procurement in the short term may be manageable.